

DR Market Announcement

J.P.Morgan

November 3, 2025

JPMorgan Chase Bank, N.A.
500 Stanton Christiana Rd.
Newark, DE 19713-2107

NASDAQ
2 Corporate Drive

Security Name: AstraZeneca PLC - Termination Announcement

CUSIP:	046353108
ADR Termination Time:	Open of Business (NY time) on February 2, 2026
Ratio:	2 American depositary shares ("ADS"): 1 Ordinary Share
Country of Incorporation:	United Kingdom
Custodian:	JPMorgan London

JPMorgan Chase Bank, N.A., as depositary ("J.P. Morgan" or the "Depositary"), has received notice from AstraZeneca PLC ("AstraZeneca or the Company") that at the general meeting held on November 3, 2025, AstraZeneca's shareholders approved the special resolution to amend the articles of association of the Company in order to facilitate what the Company has described as the harmonization of the Company's share listing structure by way of the direct listing of the Company's ordinary shares (the "AstraZeneca Shares" on the NYSE (the "Harmonized Listing Structure"). J.P. Morgan has been informed by AstraZeneca that the Direct U.S. Listing on the NYSE is expected to become effective on February 2, 2026 .

AstraZeneca has further advised J.P. Morgan that, in connection with the implementation of the Harmonized Listing Structure, it is terminating the Second Amended and Restated Deposit Agreement dated as of February 6, 2025 by and among AstraZeneca, J.P. Morgan and all registered holders ("Holders") and beneficial owners from time to time of ADRs evidencing ADSs issued thereunder (the "Deposit Agreement"). All capitalized terms used, but not otherwise defined herein, shall have the meaning given to such terms in the Deposit Agreement.

In accordance with the provisions of the Deposit Agreement, J.P. Morgan hereby notifies Holders that the Deposit Agreement is terminated effective at the open of business (New York time) on February 2, 2026 (the "Termination Time"). Please note that ADS issuance and cancellation books will be closed starting from close of business on January 27, 2026.

AstraZeneca has requested that the Depositary notify Holders that (i) as a result of the implementation of the Harmonized Listing Structure and the termination of the Deposit Agreement, existing ADSs will be mandatorily cancelled at or around the Termination Time so that for every two ADSs a Holder has immediately prior to the Termination Time such Holder will be entitled to receive one AstraZeneca Share, (ii) where Cede & Co. is the Holder, such AstraZeneca Shares will be distributed to Cede & Co. by Computershare Trust Company N.A., in its capacity as transfer agent (the "Transfer Agent"), (iii) Computershare Trust Company, N.A., in its capacity as election agent, will reach out to all Holders other than Cede & Co. seeking instructions on how their interests in the Shares shall be held and (iv) for any Holder whose ADSs cannot be exchanged for a whole number of AstraZeneca Shares, such fractional entitlements will be aggregated and sold by the

Transfer Agent with any net proceeds from the sale being allocated on a pro rata basis to such Holders. Neither J.P. Morgan nor any of its agents is involved in any of the actions described in this paragraph. Holders should contact the Company with any questions related thereto.

Holders are advised that AstraZeneca and J.P. Morgan have agreed that any and all cancellation fees payable to J.P. Morgan under the terms of the Deposit Agreement for the cancellation of the AstraZeneca ADRs held as of the ADR Termination Time will be paid by AstraZeneca.

Investor Disclosures:

JPMorgan Chase Bank, N.A. or any of its affiliates that are part of JPMorgan Chase & Co. (together, "J.P. Morgan," or the "Depository") collects fees from holders of depository receipts.

FX Disclosure:

In addition, to facilitate the administration of various depository receipt transactions, including disbursement of dividends or other cash distributions and other corporate actions, the Depository may engage the foreign exchange desk within other business units of JPMorgan Chase Bank, N.A. in order to enter into spot foreign exchange transactions to convert foreign currency into U.S. dollars.

Execution Disclosure:

J.P. Morgan may facilitate the sale and purchase of securities in accordance with the applicable deposit agreement or the terms and conditions of unsponsored depository receipts programs.

Disclaimer:

For further details relating to any of the above procedures, see the "Disclosure" page (or successor page) of www.adr.com, as updated by the Depository from time to time. This document is provided solely for informational purposes and is not a complete description of the procedures referred to therein, which may be subject to change without notice. J.P. Morgan does not accept any obligation to update this document, whether or not such procedures have changed.

© 2025 JPMorgan Chase & Co. All rights reserved.